| Description |
1 online resource (xv, 317 pages) : illustrations (some color) |
| Series |
Basic and Clinical Oncology |
|
Basic and clinical oncology.
|
| Contents |
Ch. 1. Clinical pharmacology of SERMs and pure anti-estrogens / Stephen R.D. Johnston -- ch. 2. Aromatase inhibitors : the third generation / William R. Miller -- ch. 3. Systemic therapy of metastatic breast cancer in postmenopausal patients / Carsten Rose [and others] -- ch. 4. ATAC : early breast cancer / Michael Baum -- ch. 5. Aromatase inhibitors and other agents in early-stage breast cancer / Paul E. Goss and Kathrin Strasser-Weippl -- ch. 6. Neoadjuvant therapy in postmenopausal women / J.M. Dixon -- Panel discussion 1. Therapy in postmenopausal women / Jacques M. Bonneterre and Henning T. Mouridsen -- ch. 7. Endocrine therapy for advanced breast cancer in premenopausal women / Walter Jonat -- ch. 8. Adjuvant endocrine treatment in premenopausal patients / Raimund Jakesz -- ch. 9. Adjuvant chemotherapy in breast cancer patients with hormone-receptor-positive (responsive) disease : focus on premenopausal women / Jonas C.S. Bergh -- Panel discussion 2. Therapy in premenopausal women / Gini F. Fleming and Jan G.M. Klijn -- ch. 10. Biology of premalignant lesions and pathogenesis / D. Craig Allred -- ch. 11. Estradiol-induced carcinogenesis via formation of genotoxic metabolites / Richard J. Santen [and others] -- ch. 12. Beyond tamoxifen : results of clinical trials / Norman Wolmark -- ch. 13. Clinical trials with aromatase inhibitors for the prevention of breast cancer / Mitch Dowsett -- Panel discussion 3. Chemoprevention / Trevor J. Powles and Wolfgang Eiermann -- ch. 14. Crosstalk between estrogen-receptor and growth-factor-receptor pathways as a mechanism of endocrine therapy resistance / C. Kent Osborne and Rachel Schiff -- ch. 15. ErbB2/HER-2 and other molecular pathways in estrogen-receptor-positive breast cancer : impact on endocrine resistance and clinical outcome / Christopher C. Benz -- ch. 16. Beyond antihormones in the targeted therapy of breast cancer / Robert I. Nicholson [and others] -- ch. 17. Novel therapeutics / Adrian L. Harris -- ch. 18. Surrogate biomarkers and neoadjuvant endocrine therapy / Matthew J. Ellis -- ch. 19. Aromatase localization in human breast cancer with development of new antibodies / Hironobu Sasano [and others] -- Panel discussion 4. Biology and new therapeutics / I. Craig Henderson and Manfred Kaufmann -- Panel discussion 5. Final discussion and wrap-up / Adrian L. Harris and C. Kent Osborne |
| Summary |
Because of the predominant role estrogens play in the development of breast cancer and the limited effectiveness of tamoxifen therapy, more selective therapeutics targeting estrogen signaling have been developed: selective estrogen receptor modulators (SERMs), selective estrogen receptor downregulators (SERDs), and a third generation of drugs that inhibit the aromatase required for estrogen biosyntheses. The authors examine clinical and translational research results from studies of these endocrine therapies and chemotherapies in pre- and postmenopausal women with early and advanced breast c |
| Analysis |
Endocrine therapy |
| Bibliography |
Includes bibliographical references and index |
| Notes |
Print version record |
| Subject |
Breast -- Cancer -- Endocrine aspects -- Congresses
|
|
Selective estrogen receptor modulators -- Congresses
|
|
Antineoplastic Agents, Hormonal -- therapeutic use
|
|
Breast Neoplasms -- drug therapy
|
|
Breast Neoplasms -- prevention & control
|
|
Chemotherapy, Adjuvant -- methods
|
|
MEDICAL -- Oncology.
|
|
HEALTH & FITNESS -- Diseases -- Cancer.
|
|
Breast -- Cancer -- Endocrine aspects
|
|
Selective estrogen receptor modulators
|
| Genre/Form |
proceedings (reports)
|
|
Conference papers and proceedings
|
|
Conference papers and proceedings.
|
|
Actes de congrès.
|
| Form |
Electronic book
|
| Author |
Ingle, James N., 1944-
|
|
Dowsett, Mitchell
|
| ISBN |
9781420028751 |
|
1420028758 |
|
